| Literature DB >> 30134832 |
Ian P Francis1, Epshita A Islam2, Adam C Gower3, Yazdani B Shaik-Dasthagirisaheb1, Scott D Gray-Owen2, Lee M Wetzler4,5.
Abstract
BACKGROUND: The emergence of fully antimicrobial resistant Neisseria gonorrhoeae has led global public health agencies to identify a critical need for next generation anti-gonococcal pharmaceuticals. The development and success of these compounds will rely upon valid pre-clinical models of gonorrhoeae infection. We recently developed and reported the first model of upper genital tract gonococcal infection. During initial characterization, we observed significant reproductive cycle-based variation in infection outcome. When uterine infection occurred in the diestrus phase, there was significantly greater pathology than during estrus phase. The aim of this study was to evaluate transcriptional profiles of infected uterine tissue from mice in either estrus or diestrus phase in order to elucidate possible mechanisms for these differences.Entities:
Keywords: Disease modeling; Gonorrhea; Host immune response; Microarray; Murine reproductive cycle; Neisseria gonorrhoeae; Transcriptome
Mesh:
Year: 2018 PMID: 30134832 PMCID: PMC6106831 DOI: 10.1186/s12864-018-5000-7
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Phase dependent genes are significantly associated with cell cycle processes
| Gene set source and type | Gene Set Name | Normalized Enrichment Score (NES) | Nominal | FDR q value |
|---|---|---|---|---|
| Reactome pathway | REACTOME_MITOTIC_M_M_G1_PHASES | 2.86 | 0.0000 | 0.0000 |
| Reactome pathway | REACTOME_CELL_CYCLE_MITOTIC | 2.82 | 0.0000 | 0.0000 |
| Reactome pathway | REACTOME_DNA_REPLICATION | 2.80 | 0.0000 | 0.0000 |
| Reactome pathway | REACTOME_CELL_CYCLE | 2.76 | 0.0000 | 0.0000 |
| KEGG pathway | KEGG_CELL_CYCLE | 2.67 | 0.0000 | 0.0000 |
| Reactome pathway | REACTOME_MITOTIC_PROMETAPHASE | 2.66 | 0.0000 | 0.0000 |
| Reactome pathway | REACTOME_G2_M_CHECKPOINTS | 2.65 | 0.0000 | 0.0000 |
| Reactome pathway | REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS | 2.60 | 0.0000 | 0.0000 |
| GO Biological Process | DNA_REPLICATION | 2.57 | 0.0000 | 0.0000 |
The differential activity of biologic systems in those genes identified as having significant reproductive-cycle-phase-effected expression was evaluated by GSEA. The biological processes represented in the 732 gene sets identified by GSEA as containing genes whose expression demonstrated significant phase effect are reflected in these 10 most significantly associated gene sets. Gene sets are ranked in descending order by Normalized Enrichment score and are labeled according to the MSigDB sub-collection to which they belong. The full table of identified gene sets can be found in Additional file 2
Fig. 1Leading edge genes from top phase-effect gene sets show phase-independent induction but phase-dependent induction magnitude. The infection dependent host response was evaluated by microarray analysis of mRNA extracted from infected uterine tissue collected 6 h after initial treatment with 107 gonococci or PBS. Expression levels of leading edge genes from for top gene sets identified by infection-effect GSEA are presented; “Cytokine-Cytokine Receptor Interaction” (KEGG HSA04060) (a) and “Chemokine Receptors Bind Chemokines” (R-HSA-380108) (b). For each gene, expression values (log2(expression)) are normalized to a mean of zero and standard deviation of one (z-normalized) for visual representation so that red and blue indicate z-scores of ≥2 or ≤ − 2, respectively, and white indicates a z-score of 0 (row-wise mean). Genes are presented in descending significance of infection effect t statistic (top to bottom). (N = 4 per condition except N = 3 for PBS Estrus)
Fig. 2Genes with significant phase:infection interaction effect cluster into distinct expression patterns. Reproductive phase dependent elements of the anti-GC host response were evaluated through identification of phase:infection effected genes within microarray analysis of mRNA extracted from infected uterine tissue collected 6 h after initial treatment with 107 gonococci or PBS. Expression levels of (a) All 416 genes with phase:infection FDR q < 0.25 were clustered based on their relative expression pattern across all samples. Clusters are indicated by colored sidebar and number. Rows represent genes, with log2(expression) values z-normalized (to a mean of zero and a standard deviation of one) across all samples. Colors are scaled so that red and blue indicate z-scores of ≥2 or ≤ − 2, respectively, and white indicates a z-score of 0 (row-wise mean). (b) Enlarged view of Cluster 1, comprised of genes induced specifically in estrus phase. (c) Enlarged view of Cluster 4, comprised of genes induced specifically in diestrus phase. N = 4 for all conditions except N = 3 for PBS Estrus
Gene sets significantly associated with positive phase:infection t statistics
| Gene set source and type | Gene Set Name | Normalized Enrichment Score (NES) | Nominal | FDR q value |
|---|---|---|---|---|
| Reactome pathway | REACTOME_INTERFERON_ALPHA_BETA_SIGNALING | 2.50 | 0.000 | 0.000 |
| GO Molecular Function | GO CHEMOKINE_ACTIVITY | 2.34 | 0.000 | 0.000 |
| GO Molecular Function | GO CHEMOKINE_RECEPTOR_BINDING | 2.19 | 0.000 | 0.001 |
| GO Molecular Function | GO CALMODULIN_BINDING | 1.99 | 0.000 | 0.045 |
| GO Biological Process | GO RESPONSE_TO_OTHER_ORGANISM | 1.99 | 0.000 | 0.037 |
| GO Biological Process | GO MYELOID_CELL_DIFFERENTIATION | 1.97 | 0.000 | 0.040 |
| KEGG pathway | KEGG_OLFACTORY_TRANSDUCTION | 1.95 | 0.000 | 0.043 |
| GO Molecular Function | GO G_PROTEIN_COUPLED_RECEPTOR_BINDING | 1.95 | 0.000 | 0.038 |
| BioCarta pathway | BIOCARTA_NFKB_PATHWAY | 1.95 | 0.000 | 0.036 |
| GO Molecular Function | GO ANION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | 1.93 | 0.000 | 0.040 |
| BioCarta pathway | BIOCARTA_TNFR2_PATHWAY | 1.93 | 0.000 | 0.038 |
| KEGG pathway | KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY | 1.91 | 0.002 | 0.047 |
| Reactome pathway | REACTOME_CGMP_EFFECTS | 1.90 | 0.002 | 0.049 |
| GO Biological Process | RESPONSE_TO_VIRUS | 1.87 | 0.002 | 0.064 |
| KEGG pathway | KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY | 1.86 | 0.000 | 0.071 |
| KEGG pathway | KEGG_TYPE_I_DIABETES_MELLITUS | 1.85 | 0.002 | 0.076 |
| KEGG pathway | KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY | 1.84 | 0.002 | 0.075 |
| Reactome pathway | REACTOME_OLFACTORY_SIGNALING_PATHWAY | 1.84 | 0.000 | 0.072 |
| Reactome pathway | REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION | 1.82 | 0.004 | 0.087 |
| GO Biological Process | GO DETECTION_OF_STIMULUS | 1.81 | 0.000 | 0.092 |
| GO Molecular Function | GO CYTOKINE_ACTIVITY | 1.81 | 0.000 | 0.095 |
| TF motif | GOGTTRYCATRR_UNKNOWN | 1.80 | 0.000 | 0.097 |
| BioCarta pathway | BIOCARTA_TALL1_PATHWAY | 1.79 | 0.009 | 0.098 |
| Reactome pathway | REACTOME_INTERFERON_SIGNALING | 1.79 | 0.000 | 0.097 |
| KEGG pathway | KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY | 1.79 | 0.000 | 0.095 |
| Reactome pathway | REACTOME_NUCLEOTIDE_BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING_PATHWAYS | 1.78 | 0.004 | 0.097 |
| TF motif | STTTCRNTTT_V$IRF_Q6 | 1.78 | 0.000 | 0.095 |
| Reactome pathway | REACTOME_RIG_I_MDA5_MEDIATED_INDUCTION_OF_IFN_ALPHA_BETA_PATHWAYS | 1.78 | 0.000 | 0.093 |
| GO Biological Process | DEFENSE_RESPONSE | 1.78 | 0.000 | 0.090 |
| Reactome pathway | REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX | 1.77 | 0.003 | 0.094 |
| Reactome pathway | REACTOME_NITRIC_OXIDE_STIMULATES_GUANYLATE_CYCLASE | 1.77 | 0.007 | 0.096 |
| Reactome pathway | REACTOME_HS_GAG_BIOSYNTHESIS | 1.76 | 0.007 | 0.098 |
| TF motif | GGGNNTTTCC_V$NFKB_Q6_01 | 1.73 | 0.000 | 0.132 |
| GO Biological Process | INFLAMMATORY_RESPONSE | 1.72 | 0.000 | 0.141 |
| BioCarta pathway | BIOCARTA_IL1R_PATHWAY | 1.72 | 0.009 | 0.138 |
| BioCarta pathway | BIOCARTA_CD40_PATHWAY | 1.72 | 0.007 | 0.138 |
| Reactome pathway | REACTOME_INTERFERON_GAMMA_SIGNALING | 1.71 | 0.003 | 0.135 |
| KEGG pathway | KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC | 1.71 | 0.000 | 0.143 |
| GO Cellular Component | NUCLEAR_CHROMOSOME | 1.70 | 0.007 | 0.151 |
| GO Biological Process | LEUKOCYTE_DIFFERENTIATION | 1.70 | 0.002 | 0.147 |
| GO Biological Process | RESPONSE_TO_BIOTIC_STIMULUS | 1.69 | 0.000 | 0.153 |
| GO Biological Process | IMMUNE_SYSTEM_DEVELOPMENT | 1.69 | 0.004 | 0.154 |
| GO Biological Process | IMMUNE_EFFECTOR_PROCESS | 1.68 | 0.009 | 0.157 |
| GO Biological Process | CHROMATIN_MODIFICATION | 1.68 | 0.004 | 0.160 |
| BioCarta pathway | BIOCARTA_TID_PATHWAY | 1.68 | 0.013 | 0.159 |
| GO Molecular Function | CHLORIDE_CHANNEL_ACTIVITY | 1.66 | 0.007 | 0.175 |
| GO Molecular Function | ANION_CHANNEL_ACTIVITY | 1.66 | 0.011 | 0.178 |
| Reactome pathway | REACTOME_PRE_NOTCH_TRANSCRIPTION_AND_TRANSLATION | 1.66 | 0.016 | 0.177 |
| GO Biological Process | AMINO_SUGAR_METABOLIC_PROCESS | 1.65 | 0.007 | 0.182 |
| GO Biological Process | REGULATION_OF_MYELOID_CELL_DIFFERENTIATION | 1.64 | 0.010 | 0.204 |
| KEGG pathway | KEGG_DILATED_CARDIOMYOPATHY | 1.63 | 0.000 | 0.202 |
| TF motif | V$NFKAPPAB_01 | 1.63 | 0.000 | 0.202 |
| GO Biological Process | HISTONE_MODIFICATION | 1.63 | 0.020 | 0.201 |
| Reactome pathway | REACTOME_DNA_STRAND_ELONGATION | 1.63 | 0.020 | 0.203 |
| GO Biological Process | HEMOPOIETIC_OR_LYMPHOID_ORGAN_DEVELOPMENT | 1.63 | 0.000 | 0.203 |
| GO Biological Process | HEMOPOIESIS | 1.62 | 0.000 | 0.204 |
| GO Biological Process | COVALENT_CHROMATIN_MODIFICATION | 1.62 | 0.022 | 0.201 |
| BioCarta pathway | BIOCARTA_NTHI_PATHWAY | 1.62 | 0.021 | 0.209 |
| Reactome pathway | REACTOME_TRAF6_MEDIATED_NFKB_ACTIVATION | 1.61 | 0.020 | 0.212 |
| GO Biological Process | ESTABLISHMENT_AND_OR_MAINTENANCE_OF_CHROMATIN_ARCHITECTURE | 1.61 | 0.007 | 0.213 |
| GO Biological Process | DETECTION_OF_EXTERNAL_STIMULUS | 1.61 | 0.025 | 0.210 |
| GO Cellular Component | EXTRACELLULAR_SPACE | 1.60 | 0.000 | 0.229 |
| GO Biological Process | RESPONSE_TO_BACTERIUM | 1.59 | 0.033 | 0.234 |
| Reactome pathway | REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM | 1.59 | 0.014 | 0.233 |
| GO Molecular Function | SYMPORTER_ACTIVITY | 1.59 | 0.020 | 0.238 |
| TF motif | V$CREL_01 | 1.58 | 0.000 | 0.239 |
| GO Biological Process | RESPONSE_TO_UV | 1.58 | 0.025 | 0.237 |
| BioCarta pathway | BIOCARTA_STRESS_PATHWAY | 1.58 | 0.019 | 0.234 |
| KEGG pathway | KEGG_ALLOGRAFT_REJECTION | 1.58 | 0.026 | 0.246 |
| GO Biological Process | MORPHOGENESIS_OF_AN_EPITHELIUM | 1.58 | 0.029 | 0.242 |
The differential activity of biologic systems within the phase:infection interaction effected genes was evaluated by GSEA. Seventy gene sets were identified as significantly (FDR q < 0.25) coordinately up-regulated to a greater degree (or down-regulated to a lesser degree) during infection in diestrus phase than in estrus phase. Gene sets are ranked in descending order by Normalized Enrichment score, and are labeled according to the MSigDB sub-collection to which they belong
Fig. 3Leading edge genes from top phase:infection interaction-effect gene sets. Transcript levels of leading edge genes, from GSEA identified top phase:infection interaction effect gene sets (a. Chemokine activity gene set [GO:0008009], b. Interferon alpha/beta signaling pathway [R-HSA-909733]), as measured 6 h after infection, are displayed by heatmap. Rows represent genes, with log2(expression) values z-normalized (to a mean of zero and a standard deviation of one) across all samples. Colors are scaled so that red and blue indicate z-scores of ≥2 or ≤ − 2, respectively, and white indicates a z-score of 0 (row-wise mean). Rows are arranged in descending order from top to bottom by phase:infection t statistic. N = 4 per condition except PBS estrus N = 3
Fig. 4Canonical pathways significantly associated with phase-dependent response to infection. Ingenuity Pathway Analysis was used to evaluate biological pathways that are significantly overrepresented within the 416 genes with phase:infection FDR q < 0.25. Canonical pathways with p < 0.001 by Fisher’s exact test are shown
Fig. 5Granulocyte activation and diapedesis mediators show greater induction during diestrus phase infection than in estrus. The members of the Ingenuity Pathway Analysis “Granulocyte Activation and Diapedesis” pathway are shaded according to the differential fold change in transcript level after 6 h of transcervical infection with 107 gonococci during diestrus versus estrus phase over phase specific controls (signed ratio of infection-induced fold change in diestrus phase to that in estrus phase). Colors are scaled so that red and blue indicate differential fold changes of ≥2.5 or ≤ − 2.71, respectively, and white indicates a differential fold change of 0 (no difference in fold change between phases). N = 4 for all conditions except PBS estrus N = 3
Fig. 6Chemokines generally show greater induction during infection in diestrus phase than in estrus phase. The phase-dependent effect on infection induced chemokine expression is shown as differential fold change in transcript level after 6 h of transcervical infection with 107 gonococci during diestrus versus estrus phase over phase specific controls (signed ratio of infection-induced fold change in diestrus phase to that in estrus phase). Colors are scaled so that red and blue indicate differential fold changes of ≥2.5 or ≤ − 2.71, respectively, and white indicates a differential fold change of 0 (no difference in fold change between phases). N = 4 per condition except for PBS estrus N = 3
Fig. 7Principal Component Analysis (PCA) before and after batch correction. All samples are plotted with respect to the first and second Principal Components (PC), computed using log2 (expression) values z-normalized across all samples (to a mean of zero and a standard deviation of one). PCA was performed both prior to (a) and following (b) correction for array batch effect using ComBat. Light and dark colors indicate estrus-phase and diestrus-phase samples, respectively, and gray and green indicate PBS-treated and GC-infected samples, respectively. Samples from array batches 1 and 2 are plotted as circles and squares, respectively. N = 4 for all groups except PBS Estrus N = 3